Total
0
Shares
Some members of the Epsilon team. Source: Epsilon Healthcare/ LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Epsilon Healthcare (EPN) signs a long term manufacturing agreement for Cannim’s Jamaican cannabis products
  • The two year agreement will see Epsilon’s facility produce medical cannabis products from Cannim
  • The products created will then be supplied to the Australian market and exported around the globe
  • Epsilon was up 28 per cent and is trading at 16 cents per share at 2:53 pm AEDT

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.

Cannim is a global cannabis company with a 202 hectare farm in Jamaica.

Under the two year agreement, Epsilon’s facility will produce medical cannabis products from Cannim. The product will then be supplied to the Australian market and exported around the globe.

Under the agreement, Epsilon’s manufacturing arm, THC Pharma, will receive bulk imports of dried flower for the packaging and release of Australian GMP dried flower.

Notably, this agreement is terminable at any time by either party.

First products have already been delivered and released for patient access by Epsilon under Cannim’s HummingBud brand.

These products can be prescribed now by Tetra Health – Espilon’s wholly owned clinic network.

Cannim’s Chief Operating Officer Lachlan Cameron said the agreement allowed the company to bring its Jamaican cannabis flower to Australia.

“The high quality, GMP certified production facility will ensure that we provide the best
possible expression of our product to patients in need throughout Australia and
further afield,” he said.

Epsilon’s CEO Jarrod White is also pleased with the agreement.

“Matching our high-volume EU GMP compliant Southport Facility with Cannim’s high volume GACP Jamaican medicinal cannabis places both companies in a strong position to deliver significant volumes of high-quality medicines for both the Australian and global export markets,” Mr White said.

“The partnership contemplates all areas of the Epsilon value chain, from local import and
handling of dried product expertise, to export, and assisting in the logistics and distribution of the final product. This is reflective of the significant progress and capability
improvements at our Southport facility in the preceding 12 months.”

On the market, Epsilon was up 28 per cent and is trading at 16 cents per share at 2:53 pm AEDT.

EPN by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert

" Rhythm Biosciences (ASX:RHY) achieves CE Mark for ColoSTAT

Cancer diagnostic technology company Rhythm Biosciences (RHY) has achieved CE Mark certification for ColoSTAT.
EMVision Medical Devices (ASX:EMV) - CEO, Ron Weinberger

" EMVision Medical Devices (ASX:EMV) reports more strong results

Medical device maker EMVision (EMV) is spiking on the ASX today after releasing further results from a pilot clinical trial of its brain
ECS Botanics (ASX:ECS) - Managing Director and Founder, Alex Keach

" ECS Botanics’ (ASX:ECS) subsidiary buds $4.9m supply agreement

ECS Botanics’ (ECS) subsidiary has secured a $4.9 million agreement to supply resin to Australian cannabis company, Cannvalate.
Arovella Therapeutics (ASX:ALA) - CEO and Managing Director, Dr Michael Baker

" Arovella Therapeutics (ASX:ALA) receives $524,000 R&D tax refund

Arovella Therapeutics (ALA) has received a refund from the Australian Taxation Office (ATO) of just over $524,000 for the financial year.